Sep 22, 2025, 06:33
Antiphospholipid Syndrome (APS) in Pregnancy – Key Takeaways
Dr. Mukesh, Assistant Professor of Clinical Immunology and Rheumatology at King George’s Medical University (KGMU), posted on X:
”Antiphospholipid Syndrome (APS) in Pregnancy – Key Takeaways
- APS affects 0.5% of the population but is a major cause of recurrent pregnancy loss (RPL), preeclampsia and FGR.
- Pathogenesis: “Two-hit model” → aPL antibodies trigger endothelial/placental dysfunction → thrombosis + insufficiency.
- Lupus anticoagulant (LA) = strongest predictor of poor outcomes.
- Standard of care: Low-dose aspirin (LDA) + LMWH → boosts live birth rates.
- Hydroxychloroquine (HCQ) reduces preterm birth and improves placental health in high-risk cases.
- Refractory APS? → Novel options: TNF-α inhibitors, complement blockers (eculizumab), nitric oxide modulators, statins.
- APS + SLE overlap = compounded risks → needs aggressive, multidisciplinary management.
- CAPS (catastrophic APS) = rare but lethal; pregnancy can trigger it (mortality ~36%).
- New 2023 ACR/EULAR criteria improve APS classification and risk stratification in pregnancy.
Bottom line: Early diagnosis, tailored therapy, and multidisciplinary care = better outcomes for mom and baby.”
Read the full review here.
Title: Antiphospholipid syndrome in pregnancy: a comprehensive literature review
Authors: Viorela Romina Murvai, Radu Galiș, Anca Panaitescu, Casandra Maria Radu, Timea Claudia Ghitea, Paula Trif, Miruna Onița-Avram, Alexandra Alina Vesa, Anca Huniadi

Stay updated with Hemostasis Today.
Alexandra Alina Vesa
Anca Huniadi
Anca Panaitescu
Antiphospholipid Syndrome
APS
Aspirin
BioMed Central
BMC
Casandra Maria Radu
Catastrophic APS
Health
Hematology
Hemostasis
Hemostasis Today
Heparin
Hydroxychloroquine
Immunology
in Pregnancy
King George's Medical University (KGMU)
LMWH
Low-Molecular-Weight Heparin
Lupus anticoagulant (LA)
Medicine
Miruna Onița-Avram
Mukesh
Paula Trif
Pregnancy
Radu Galiș
Recurrent Pregnancy Loss (RPL)
Rheumatology
thrombosis
Timea Claudia Ghitea
Viorela Romina Murvai
-
Jul 13, 2026, 16:06Dino Mehic: Honored to Receive the ISTH Early Career Top Reviewer Awards
-
Jul 13, 2026, 16:01Advancing DIC Diagnosis in Cirrhosis Through Disease-Specific Risk Stratification – JTH
-
Jul 13, 2026, 15:52Joshua Muia: Presenting Our Research on ADAMTS13/VWF Dysregulation in Sepsis at ISTH 2026
-
Jul 13, 2026, 15:42Marc Carrier: Important New Data From the API-CAT Trial on Recurrent VTE During Extended Apixaban Therapy
-
Jul 13, 2026, 15:23Akshat Jain: 5 Key Clinical Takeaways from ISTH 2026
-
Jul 13, 2026, 15:15Alfonso J. Tafur: Insights on Periprocedural DOAC Management in Atrial Fibrillation at ISTH 2026
-
Jul 13, 2026, 14:42Bruno Pougault: The Global Momentum Behind Innovation in Thrombosis and Hemostasis
-
Jul 13, 2026, 14:34Julie Vassart: Optimizing DOAC Detection in an Evolving Anticoagulant Landscape at ISTH 2026
-
Jul 13, 2026, 13:57Heghine Khachatryan: The Diagnostic Dilemma of Non-Criteria Obstetric APS